Veracyte-VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

Key Takeaways Testing revenues totaled $122.3 million, up 14% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 24% and 5%, respectively. Testing volume improved 18% year over year to 42,441 tests. Product revenues fell 8% year over year to$ 3.6 million. Biopharmaceutical and other revenues of $4.3 million reflected a 21% increase from the prior-year quarter's figure. Margins Veracyte, Inc. (VCYT) delivered second-quarter 2025 adjusted earnings of 44 cents per share, which ma ...